OrthoPediatrics Q3 revenue $61.2M (+12% YoY); adjusted EBITDA up 56% to $6.2M; raises FY2025 revenue guidance

ORTHOPEDIATRICS CORP

2025-Q3 EPS reported -$1.26 revenue$174,743,000

Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.
GAAP EPS -$0.50 vs -$0.34; non-GAAP EPS -$0.24 vs -$0.18; net loss $11.8M vs $7.9M.
Adjusted EBITDA $6.2M (+56% YoY); free cash flow usage improved to $3.4M from $11.6M.
FY2025 revenue guidance raised to $233.5-234.5M (+14-15%); adjusted EBITDA guidance reiterated $15-17M.
Recorded $2.3M restructuring charge and $2.3M intangible impairment (ApiFix, Telos, Medtech).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.